EGFR and non-small cell lung carcinoma: Clinical trials with a humanised murine chimeric monoclonal antibody to EGFR (C225, Cetuximab) in combination with chemotherapy or radiotherapy have shown significant clinical activity in advanced colorectal carcinomas (Cunningham et al, 2004) squamous cell carcinomas of the head and neck (Vermorken et al, 2007), and non-small cell lung cancer (NSCLC) (Janne et al, 2004; Giaccone, 2005).